Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ningetinib + Gefitinib in EGFR-Mutated, T790M-Negative NSCLC
NCT03758287Phase 2Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ningetinib in non-small cell lung cancer (NSCLC), sponsored by Sunshine Lake Pharma. Started Nov 2016; status: completed.
02
Drugs
ningetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03758287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03758287.